Leading brokerage houses have recently cast their spotlight on seven Indian companies, initiating fresh coverage and issuing 'buy' or 'overweight' ratings with significant upside potential. These recommendations, updated on September 2, 2026, suggest gains ranging from 16% to a remarkable 55% for investors.
The selected brokerage stock picks span a diverse range of industries, from pharmaceuticals and asset management to infrastructure and insurance, highlighting the varied opportunities analysts are identifying in the Indian market.
Fresh Brokerage Interest: Key Picks
Zydus Lifesciences: Up to 55% Upside
Globe Capital Markets has initiated coverage on Ahmedabad-based Zydus Lifesciences with an 'Overweight' rating and a target price of Rs 1,782, projecting an impressive 55% upside. The firm highlights Zydus's diversified global portfolio, encompassing oral products, bulk APIs, vaccines, consumer wellness, and cardiology. Strong domestic demand, with India branded formulations growing 20% year-on-year, coupled with new launches like Saroglitazar in the US and Desidustat in China, are expected to fuel future growth.
Medi Assist Healthcare Services: 42% Growth Potential
InCred Equities has assigned a 'Buy' rating to Medi Assist Healthcare Services, India's largest health insurance Third-Party Administrator (TPA), setting a target price of Rs 477, indicating a 42% upside. Medi Assist manages claims, operates a vast 20,000-hospital cashless network, and administers government health schemes. InCred believes that while FY26 may represent a challenging period, identifiable drags are expected to subside by FY27, positioning the debt-free franchise for robust growth.
SBI Funds Management: 28% Upside Projected
Motilal Oswal Financial Services recommends a 'Buy' for SBI Funds Management, with a target price of Rs 720, forecasting a 28% upside. The brokerage firm views SBI Funds as a high-quality, structurally compounding Asset Management Company (AMC) franchise. Key drivers include its market leadership, the extensive SBI-led distribution network, the underpenetrated mutual fund industry, and significant operating leverage. Motilal Oswal anticipates a 13% Mutual Fund AUM CAGR and a 14% revenue CAGR between FY26-28.
General Insurance Corporation of India (GIC Re): 25% Upside
Angel One has initiated coverage on General Insurance Corporation of India (GIC Re) with a 'Buy' rating and a target price of Rs 441, suggesting a 25% upside. Angel One forecasts an annual gross premium growth of 7% and an improved combined ratio by FY28E. This improvement is expected to be driven by pruning the crop book and sustained profitability from the international portfolio, supported by GIC Re's dominant domestic franchise and strong solvency.
Seamec: 23% Potential Gain
360 One Capital has issued a 'Buy' rating for Seamec, a provider of niche underwater/subsea marine services, with a target price of Rs 2,058, implying a 23% upside. Seamec operates the world's largest fleet of diving support vessels (DSVs). The demerger of its parent, HAL Offshore, and the anticipated merger of the Marine segment over the next two to three years are expected to significantly boost EBITDA, with demand for DSVs remaining structurally strong.
CemIndia Projects: Aiming for 22% Rise
Anand Rathi Share & Stock Broker has placed a 'Buy' rating on CemIndia Projects, an EPC contractor, with a target price of Rs 1,504, indicating a 22% upside. CemIndia is recognized for its capabilities in technically complex infrastructure segments, including marine structures, underground metros, and airports, where high entry barriers exist. The acquisition by the Adani Group is seen as a structural inflection point, strengthening the balance sheet and providing access to a substantial project pipeline.
Entero Healthcare Solutions: 16% Upside Forecast
ICICI Securities has initiated coverage on Entero Healthcare Solutions with a 'Buy' rating and a target price of Rs 2,100, forecasting a 16% upside. Entero has rapidly established itself as a top-three distributor of healthcare products in India, operating with a superior margin profile. The firm's strong track record of acquiring 22 entities in the last four years and its expansion into the medical devices market are expected to drive robust revenue, EBITDA, and PAT CAGR over FY26-29E.
Disclaimer: This article summarizes brokerage views for informational purposes only and does not constitute investment advice. Readers should consult a qualified financial advisor before making any investment decisions.